150
Participants
Start Date
December 31, 2003
Primary Completion Date
April 30, 2007
Study Completion Date
June 30, 2007
MEDI-522
IV at a concentration of 50 mg/mL and 10mL vials
Docetaxel + Prednisone* + Zoledronic Acid
IV 75 mg/m2 IV 3-4 mg 5 mg
University Hospital Erasme, Brussels
A.Z. Middelheim, Antwerp
Borsod County Teaching Hospital, Miskolc, H
Szolnoki Mav Hospital, Szolnok
Az Groeninge, Kortrijk
H.-Hartziekenhuis Medische Onocology-Hematologie, Roeselare
SUNY Down State Medical Center, Brooklyn
North Shore Hematology Oncology Assoc., PC, East Setauket
VA Medical Center, Northport
Virginia Cancer Institute, Richmond
Raleigh Hematology Oncology Association, Raleigh
Santee Hematology/Oncology, Sumter
Florida Cancer Specialist, Fort Myers
The Florida Wellcare Alliance, L.C., Inverness
Clinical Research Consultants, Inc., Hoover
The Sarah Cannon Cancer Center, Nashville
Associates in Oncology and Hematology, Chattanooga
Thompson Cancer Survival Center, Knoxville
North Mississippi Hematology & Oncology Associates, Ltd., Tupelo
Sapir Medical Center - Meir Hospital, Kfar Saba
The Community Hospital, Munster
Rabin Medical Center, Petah Tikva
Hubert H. Humphrey Cancer Center, Robbinsdale
Ingalls Hospital, Harvey
Tel Aviv Sourasky Medical Center, Tel Aviv
Hematology Oncology Services, LLC, New Orleans
Highlands Oncology Group, P.A., Springdale
Arizona Hematology-Oncology, P.C., Tucson
New Mexico Oncology Hematology, Consultants Ltd., Albuquerque
Comprehensive Cancer Center of Nevada, Las Vegas
VA Sierra Nevada Health Care System, Reno
San Bernardino Urological Associates, San Bernardino
Saint Francis Memorial Hospital, San Francisco
Hawaii Medical Consultants, Honolulu
Western Washington Oncology, Inc., P.S., Lacey
Blokhin Cancer Research Center, Moscow
Russian Research Center of Radiology, Moscow
Semashko Central Clinical Hospital, Moscow
Arkhangelsk Regional Oncology Center, Arkhangelsk
City Clinical Oncology Dispensary, Saint Petersburg
Medical Rediological Research Centre of Ran, Obninsk
Voronezh Regional Oncology Clinical Center, Voronezh
Kazan City Oncology Center, Kazan'
Samara Regional Oncology Center, Samara
Chelyabinsk Regional Oncology Center, Chelyabinsk
South Valley Medical Plaza, Gilroy
Stanford Advanced Medical Center, Stanford
Hemotology/Oncology Associates, Lake Worth
Clinical Research Services, Bismarck
Samodzielny Publiczny Wojewodzki Szpital Zespolony, Słupsk
University of Chicago, Chicago
Washington University School of Medicine, St Louis
VA Western New York Healthcare System, Buffalo
Columbia Presbyterian Medical Center, New York
University of Cincinnati, Barrett Cancer Center, Cincinnati
Danville Hematology and Oncology, Danville
Centre Hospitalier de L'Universite de Montreal, Montreal
Lead Sponsor
MedImmune LLC
INDUSTRY